Human Influenza viruses IgG,FLU ELISA Kit |
201-12-1767 |
SunredBio |
96 tests |
EUR 528 |
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
Human IgG antibody Laboratories manufactures the seasonal flu diagnostic elisa kit 2017 reagents distributed by Genprice. The Seasonal Flu Diagnostic Elisa Kit 2017 reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact influenza elisa. Other Seasonal products are available in stock. Specificity: Seasonal Category: Flu Group: Diagnostic Elisa
Rabbit FLU ELISA Kit |
Abclonal |
96Tests |
EUR 625.2 |
Porcine FLU ELISA Kit |
Abclonal |
96Tests |
EUR 625.2 |
Rat FLU ELISA Kit |
Abclonal |
96Tests |
EUR 625.2 |
Bovine FLU ELISA Kit |
Abclonal |
96Tests |
EUR 625.2 |
Canine FLU ELISA Kit |
Abclonal |
96Tests |
EUR 625.2 |
Anserine FLU ELISA Kit |
Abclonal |
96Tests |
EUR 625.2 |
Goat FLU ELISA Kit |
Abclonal |
96Tests |
EUR 625.2 |
Diagnostic Elisa information
Recombinant Trypanosoma Vivax Diagnostic antigen Protein (aa 21-107) (E. coli) [His] |
VAng-Wyb8564-500g |
Creative Biolabs |
500 µg |
EUR 9794.4 |
Description: Trypanosoma Vivax Diagnostic antigen protein, recombinant protein. |
Recombinant Trypanosoma Vivax Diagnostic antigen Protein (aa 21-111) (E. coli) [His] |
VAng-Wyb8566-100g |
Creative Biolabs |
100 µg |
EUR 4002 |
Description: Trypanosoma Vivax Diagnostic antigen protein, recombinant protein. |
Recombinant Trypanosoma Vivax Diagnostic antigen Protein (aa 21-111) (E. coli) [His] |
VAng-Wyb8566-500g |
Creative Biolabs |
500 µg |
EUR 9794.4 |
Description: Trypanosoma Vivax Diagnostic antigen protein, recombinant protein. |
Seasonal H1N1 Hemagglutinin Peptide |
5231P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: Seasonal H1N1 Hemagglutinin peptide |
Seasonal H1N1 Hemagglutinin Peptide |
5235P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: Seasonal H1N1 Hemagglutinin peptide |
Seasonal H1N1 Hemagglutinin Peptide |
5239P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: Seasonal H1N1 Hemagglutinin peptide |
Seasonal H1N1 Neuraminidase Peptide |
5247P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: Seasonal H1N1 Neuraminidase peptide |
Seasonal H1N1 Hemagglutinin Antibody |
5231-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: Seasonal H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
Seasonal H1N1 Hemagglutinin Antibody |
5231-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: Seasonal H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
Seasonal H1N1 Hemagglutinin Antibody |
5235-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: Seasonal H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
Seasonal H1N1 Hemagglutinin Antibody |
5235-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: Seasonal H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
Seasonal H1N1 Hemagglutinin Antibody |
5239-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: Seasonal H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
Seasonal H1N1 Hemagglutinin Antibody |
5239-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: Seasonal H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
Seasonal H1N1 Neuraminidase Antibody |
5247-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: Seasonal H1N1 Neuraminidase Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
Seasonal H1N1 Neuraminidase Antibody |
5247-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: Seasonal H1N1 Neuraminidase Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
Seasonal H1N1 Hemagglutinin Antibody |
24917-100ul |
SAB |
100ul |
EUR 468 |
Seasonal H1N1 Hemagglutinin Antibody |
24919-100ul |
SAB |
100ul |
EUR 468 |